| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d20e268c659eae999447fc2be8aa492 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-46 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate |
2015-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b608be34cc4af0852e59e639e306fd1c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d47f2327f35940fa3e58e97a6667f8d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06e70a0bdf95f1159ca840f95c811c3c |
| publicationDate |
2020-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3689350-A1 |
| titleOfInvention |
Ophthalmic composition comprising atropine or atropine sulphate |
| abstract |
Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein. |
| priorityDate |
2014-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |